{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"734"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"The duration of objective response is measured from the date of the first tumor response assessment with an Investigator's Overall Response of CR or PR (whichever status is recorded first) until the date of progression or death. DoR is presented by subject.","groups":[{"description":"Duration of response for patients with soft tissue sarcoma cancer who received 80 mg/m2 of EDO-S101 administered over 1 hour.","id":"OG000","title":"Tinostamustine (EDO-S101) - Phase 2 STS Cohort"},{"description":"Duration of response for patients with ovarian cancer who received 80 mg/m2 of EDO-S101 administered over 1 hour.","id":"OG001","title":"Tinostamustine (EDO-S101) - Phase 2 OC Cohort"},{"description":"Duration of response for patients with solid tumour who received 60 mg/m2 of EDO-S101 administered over 1 hour.","id":"OG002","title":"Tinostamustine (EDO-S101) - Sub Study 1 (SS1)"}],"paramType":"NUMBER","populationDescription":"Number of participants is zero in some of the arms as no participants achieved a response of CR or PR.","reportingStatus":"POSTED","timeFrame":"From patient's first overall response of CR or PR, until disease progression/subsequent anti-cancer therapy/death from any cause, up to 24 months.","title":"Maximum Duration of Response (DoR) Time for Phase 2 and Sub Studies","type":"SECONDARY","unitOfMeasure":"days"}